LRMR Logo

Larimar Therapeutics, Inc. (LRMR) 

NASDAQ
Market Cap
$241.19M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
13 of 959
Rank in Industry
10 of 550

Largest Insider Buys in Sector

LRMR Stock Price History Chart

LRMR Stock Performance

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Insider Activity of Larimar Therapeutics, Inc.

Over the last 12 months, insiders at Larimar Therapeutics, Inc. have bought $38.02M and sold $0 worth of Larimar Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Larimar Therapeutics, Inc. have bought $20.2M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Flynn James E (* Director by Deputization) — $1.42B. Hamilton Thomas Edward (director) — $999,996. THOMAS FRANK E (director) — $22,000.

The last purchase of 4,290,617 shares for transaction amount of $37.5M was made by Flynn James E (* Director by Deputization) on 2024‑02‑16.

List of Insider Buy and Sell Transactions, Larimar Therapeutics, Inc.

2024-02-16Purchase* Director by Deputization
4.29M
6.6831%
$8.74$37.5M-40.61%
2024-02-16Purchasedirector
57,208
0.0891%
$8.74$499,998-40.61%
2024-02-14Purchasedirector
2,000
0.0064%
$11.00$22,000-36.37%
2023-12-07PurchaseChief Development Officer
5,000
0.0119%
$3.73$18,662+103.31%
2023-05-17PurchasePresident and CEO
5,000
0.0114%
$3.71$18,525+8.67%
2023-05-17PurchaseChief Financial Officer
5,000
0.0115%
$3.73$18,632+8.67%
2023-05-17Purchasedirector
2,750
0.0063%
$3.73$10,258+8.67%
2022-09-16Purchase
11.11M
49.2054%
$3.15$35M+21.88%
2022-09-16Purchasedirector
317,460
1.4059%
$3.15$999,999+21.88%
2022-09-16PurchasePresident and CEO
31,746
0.1406%
$3.15$100,000+21.88%
2022-09-16PurchaseChief Financial Officer
31,746
0.1406%
$3.15$100,000+21.88%
2021-06-30Purchase
685,710
3.341%
$8.75$6M-2.39%
2021-06-30Purchasedirector
56,710
0.2763%
$8.75$496,213-2.39%
2018-06-28SaleSee Remarks
32,000
0.1034%
$10.00$320,000-47.50%
2018-03-07SaleSee Remarks
5,000
0.0194%
$10.00$50,000-8.25%
2017-10-13Purchasedirector
20,000
0.0343%
$1.95$38,988+75.12%
2017-07-11PurchaseChief Medical Officer
20,000
0.037%
$1.70$33,900+63.77%
2017-05-11PurchaseChief Medical Officer
19,600
0.0729%
$4.40$86,240-12.41%
2017-05-10PurchaseChief Medical Officer
400
0.0014%
$4.40$1,760-15.92%
2016-12-19Purchasedirector
20,000
0.0742%
$3.23$64,580+16.61%

Insider Historical Profitability

9.25%
Flynn James E* Director by Deputization
6151406
9.6407%
$3.7871<0.0001%
Hamilton Thomas Edwarddirector
564798
0.8852%
$3.7830+21.88%
THOMAS FRANK Edirector
2000
0.0031%
$3.7810
BEN-MAIMON CAROLEPresident and CEO
266829
0.4182%
$3.7820+15.27%
Hughes Thomas E.See Remarks
125247
0.1963%
$3.7824+20.01%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Deerfield Management$161.15M33.2821.23M+25.33%+$32.57M0.39
RA Capital Management, L.P.$45.88M9.486.05MNew+$45.88M0.05
Janus Henderson$30.46M6.34.02M+52.25%+$10.45M0.02
Blue Owl Capital Holdings Lp$30.32M6.263.99M+16.99%+$4.4M2.54
Goldman Sachs$25.94M5.363.42M+2,452.98%+$24.92M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.